# Clinical Trials Data ERBB2 - Document 52

# S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

## Clinical Trial: https://clinicaltrials.gov/study/NCT00896727

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of primary invasive adenocarcinoma of the breast\n\n \* Stage I-IIIA disease (T1-3, N0-1, M0)\n\* Enrolled on clinical trial SWOG-9313\n\* Tumor tissue available for testing\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients from SWOG 9313 consented to banking",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not specify\*\* whether an ERBB2 (also known as HER2) mutation is required, an exclusion criteria, or simply not relevant. The criteria only mention having a diagnosis of primary invasive adenocarcinoma of the breast, being enrolled in SWOG-9313, and having tumor tissue available. Therefore, we cannot determine eligibility based on ERBB2 status alone. More information is needed.